The immune boosting benefits of a tuberculosis vaccine can be seen in infants more than one year after vaccination, according to a new study. The research, led by the Murdoch Children's Research ...

Bacillus Calmette-Guérin (BCG) vaccines are given to more than 100 million children every year, but there is considerable debate regarding the effectiveness of BCG vaccination in preventing ...

Administering the Bacillus Calmette-Guérin (BCG) vaccine during the active phase of COVID-19 may help protect against the development of long COVID. A phase 3 clinical trial initiated in early 2020 ...

Infants who received BCG [bacille Calmette-Guérin] vaccination at birth had protection against tuberculosis into early childhood, but that protection largely disappeared in only a few years, according ...

In a recent study posted to the bioRxiv* preprint server, researchers tested the effectiveness of the Bacillus Calmette Guérin (BCG) vaccine in severe acute respiratory syndrome coronavirus 2 ...

Amid debate on the effectiveness of the tuberculosis vaccine, a new study suggests that the vaccine is protective against TB in children under 5, but adolescents and adults in high-burden countries ...

During the frightening early weeks of the COVID-19 pandemic in March of 2020, Kiehl Sundt, of Sequim, Washington, became one of the first people on Earth to receive an experimental dose of Moderna’s ...

Using zebrafish “Avatars”, an animal model developed by the Cancer Development and Innate Immune Evasion lab at the Champalimaud Foundation (CF), led by Rita Fior, Mayra Martínez-López – a former PhD ...

Please provide your email address to receive an email when new articles are posted on . Researchers observed the potential protective effect when accounting for death as a competing event. Patients ...

A single injection of the 102-year-old tuberculosis vaccine, BCG, has proven effective at triggering an immune response in mice and shrank their liver cancer tumors, according to research by UC Davis ...

Researchers headed by a team at Pitt University, in collaboration with scientists at Cornell University, have developed a self-destructing, intravenous (i.v.) Bacillus Calmette-Guérin (BCG) vaccine ...

Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its bladder cancer med is still one to watch as it competes with heavy hitt | ...